Helix BioPharma Corp. Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2017 and an update on the Company’s research and development programs.